New combo therapy targets Hard-to-Treat myeloma in early trial
NCT ID NCT05391750
First seen Feb 23, 2026 · Last updated May 16, 2026 · Updated 12 times
Summary
This early-phase study tests the safety and best dose of two drugs—venetoclax and tocilizumab—in people with a specific genetic subtype of multiple myeloma (t(11;14)) that has returned or stopped responding to treatment. The trial includes both African American and non-African American participants. The goal is to find a dose that limits side effects while potentially killing more cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.